News
HKMPF
18.00
NaN%
--
Hikma executives receive shares as long-term incentive awards vest
TipRanks · 5d ago
Hikma steps up $250m buyback, cancels further shares
TipRanks · 6d ago
Weekly Report: what happened at HKMPF last week (0406-0410)?
Weekly Report · 6d ago
Hikma trims executive share awards amid share price volatility
TipRanks · 04/09 15:48
Hikma tightens free float as buyback tops 3.9 million shares
TipRanks · 04/07 08:47
Weekly Report: what happened at HKMPF last week (0330-0403)?
Weekly Report · 04/06 09:13
Hikma Steps Up $250m Buyback, Lifts Treasury Holdings
TipRanks · 03/30 09:59
Weekly Report: what happened at HKMPF last week (0323-0327)?
Weekly Report · 03/30 09:13
Hikma Advances $250m Buyback, Tightening Share Count and Boosting EPS
TipRanks · 03/23 11:02
Weekly Report: what happened at HKMPF last week (0316-0320)?
Weekly Report · 03/23 09:13
Hikma Releases 2025 Annual Report and 2026 AGM Notice
TipRanks · 03/18 10:15
Hikma steps up $250m buyback, cancels newly repurchased shares
TipRanks · 03/16 09:33
Weekly Report: what happened at HKMPF last week (0309-0313)?
Weekly Report · 03/16 09:12
Hikma PDMR Increases Stake with £74,400 Share Purchase
TipRanks · 03/11 10:12
Weekly Report: what happened at HKMPF last week (0302-0306)?
Weekly Report · 03/09 09:13
Hikma Details Weekly Disclosure Plan as $250m Buyback Cuts Share Count
TipRanks · 03/09 07:17
Hikma Steps Up $250m Buyback With Fresh Share Repurchase
TipRanks · 03/06 07:19
Hikma price target lowered to 1,800 GBp from 2,300 GBp at Berenberg
TipRanks · 03/05 18:05
Hikma Advances $250m Buyback With Fresh Purchase and Share Cancellation
TipRanks · 03/05 07:25
Berenberg Bank Remains a Buy on Hikma Pharmaceuticals (HIK)
TipRanks · 03/04 23:15
More
Webull provides a variety of real-time HKMPF stock news. You can receive the latest news about Hikma Pharma through multiple platforms. This information may help you make smarter investment decisions.
About HKMPF
Hikma Pharmaceuticals PLC is a multinational pharmaceutical company engaged in the development, manufacturing and marketing of a broad range of generic, branded and non-licensed pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Generics. It supplies hospitals across its markets with generic and specialty injectable products, supported by its manufacturing facilities in the United States (US), Europe and Middle East/North Africa (MENA). It supplies branded generic and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. It supplies oral, respiratory and other generic and specialty products to the North American retail market. Its manufacturing facilities in the US supply generic and specialty products to the US and Canada markets across a broad range of therapeutic areas, including respiratory, oncology and pain management.